Geriatrics · AgingTrial Updateclinicalmid-term

100-Year Human Aging Study Aims to Validate Surrogate Endpoints in Longevity Medicine

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/2/2026, 6:30:49 AM

Assessment confidence: 83% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The 100-Year Human Aging Study aims to validate surrogate endpoints that could revolutionize drug development in aging-related therapies. Success in this trial may lead to the identification of new biomarkers, significantly impacting clinical strategies and research directions in geriatrics. Regulatory context from FDA (Advancing Novel Surrogate Endpoints For Rare Disease Drug Development Workshop - 05/18/2026) supports the near-term read. Assessment grounded in 22 ranked evidence items (20 high-relevance).

Strategic Assessment

Success in this study may lead to new biomarkers for aging and impact drug development strategies targeting age-related diseases. The strongest clinical anchor is Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) (ClinicalTrials.gov), sponsor/company relevance (novartis). In Geriatrics · Aging, 8 regulatory and 3 competitive items passed relevance filtering for clinical trial sponsors.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise. This trial could provide critical data for longevity medicine, influencing future research and development in aging-related therapies.

Regulatory Outlook

Regulatory risk is concentrated around Advancing Novel Surrogate Endpoints For Rare Disease Drug Development Workshop - 05/18/2026 (FDA). Moderate corpus alignment. Relevant agencies in corpus: FDA, MHRA. The validation of new biomarkers could influence regulatory pathways for aging-related therapies, affecting approval processes and compliance requirements.

Key Risks

Elevated medium regulatory exposure for clinical trial sponsors could delay market entry or constrain labeling if agency review intensifies.
Competitive risk from Humanexa Signals (Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise) could weigh on clinical trial sponsors through competitive crowding and share erosion if follow-through weakens.

Key Opportunities

If successful, the study could open new avenues for therapies targeting age-related diseases, potentially increasing market share for companies involved in longevity medicine.
Success in this study may lead to new biomarkers for aging and impact drug development strategies targeting age-related diseases.

What Would Change This Assessment

This becomes more urgent if Monitor enrollment numbers and interim results for predictive health measurements and their correlation with mortality.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Advancing Novel Surrogate Endpoints For Rare Disease Drug Development Workshop - 05/18/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Clinical trials for medicines: MHRA phase I accreditation scheme
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
FDA Virtual Workshop on Digital Health Technologies and Statistical Considerations for Digitally-Derived Endpoints in Clinical Trials - 08/27/2026
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
Corporate report: Human Medicines Regulations (2012) Advisory Bodies Annual Report 2025
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Clinical trials for medicines: collection, verification and reporting of safety events
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Clinical trials for medicines: Clinical Trials Regulations transitional arrangements
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Guidance: Clinical trials for medicines: roles and responsibilities
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Clinical trials for medicines: ending a clinical trial
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Study of Varipulse Catheter in Participants With Paroxysmal Atrial Fibrillation Under Optimized Sedation
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Impro
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
A Clinical Trial to Assess the Effect of AP-Brain Collagen Peptides on the Improvement of Attention, Focus, and Memory in Stressed But Otherwise Healthy Individuals
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise
Humanexa Signalsmedium relevance
Moderate corpus alignment
Mobile App-Delivered ACT Shows Efficacy in PTSD Treatment in China
Humanexa Signalsmedium relevance
Moderate corpus alignment

First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
High-flow nasal cannula oxygenation in sedated endoscopy for high-risk obstructive sleep apnea patients: study protocol for a multicentre randomised controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness of ferumoxtran-enhanced macrophage-specific-MRI and PSMA-PET/CT versus ePLND for nodal staging in primary prostate cancer: a decision analysis based on updated phase-3 trial data.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Ethnopharmacological potential and mechanistic study of Platycodon grandiflorum stems and leaves and Lonicera japonica stems and leaves against acute lung injury.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

clinical trial sponsors
aging-related therapy developers
biomarker companies

Commercial impact

medium

If successful, the study could open new avenues for therapies targeting age-related diseases, potentially increasing market share for companies involved in longevity medicine.

Regulatory impact

medium

The validation of new biomarkers could influence regulatory pathways for aging-related therapies, affecting approval processes and compliance requirements.

What to watch

Monitor enrollment numbers and interim results for predictive health measurements and their correlation with mortality.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.